How race and ethnicity affect treatment outcomes in breast cancer patients using specific inhibitors
Official title: Impact of race and ethnicity on outcomes in patients with hormone receptor-positive breast cancer treated with CDK4/6 inhibitors
Funded at Baylor College of Medicine · NIH-10932935 · Data updated 2026-11-12
This study is looking at how well a new treatment works for hormone receptor-positive breast cancer in African American women compared to European American women, and it wants to understand how genetics, sticking to treatment, and social factors might affect their outcomes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 21, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $36,264 |
| NIH project number | 5P20CA284971-02 |
| Project ID | NIH-10932935 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with hormone receptor-positive breast cancer, particularly those who are African American.
✕Less likely to help
Patients with other subtypes of breast cancer or those who do not identify as African American may not receive direct benefits from this research.
What this research studies
This research investigates the differences in treatment outcomes for hormone receptor-positive breast cancer patients, particularly focusing on African American women compared to European American women. It examines the effectiveness of CDK4/6 inhibitors, a new treatment strategy, and explores the roles of genetic factors, medication adherence, and social determinants of health in these outcomes. By analyzing data from various databases, including The Cancer Genomic Atlas, the study aims to uncover the reasons behind the disparities in survival rates among different racial and ethnic groups.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies and outcomes for African American women with breast cancer.
How similar studies have gone: Previous studies have shown disparities in treatment outcomes based on race and ethnicity, indicating that this research is building on established findings rather than exploring a completely novel approach.
Where this research is happening
-
Baylor College of Medicine
Houston, United States Active
Researchers
- Principal investigator: Kaipparettu, Benny Abraham — Baylor College of Medicine
- Study coordinator: Kaipparettu, Benny Abraham
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.